吉非替尼一线治疗老年晚期非小细胞肺癌临床观察  

Clinical observation of trment of elderly patients with advanced non-small cell lung cancer by gefitinib

作　　者：刘剑[1] 刘地发[1] 储建华[1] 

机构地区：[1]南通大学附属海安医院,江苏南通226601

出　　处：《现代肿瘤医学》2010年第8期1540-1542,共3页Journal of Modern Oncology

摘　　要：目的:观察表皮生长因子受体酪氨酸激酶抑制剂吉非替尼单药一线治疗老年晚期非小细胞肺癌的疗效和不良反应。方法:2006年2月至2008年12月36例65岁以上晚期非小细胞肺癌患者进入研究,所有患者均为Ⅲ-Ⅳ期。口服吉非替尼250mg/d,至病情进展或者不能耐受不良反应。结果:36例均可评价疗效和不良反应。治疗后2个月进行评价,RR为41.67%(15/36)、DCR86.11%(31/36)。用药后最常见的不良反应为Ⅰ、Ⅱ度皮疹25例(52.78%),腹泻11例(30.56%),皮肤瘙痒5例(13.89%),皮肤干燥5例(13.89%),肝功异常2例(5.56%)。TTP为3.5-23.8个月,中位TTP8.2个月。结论:吉非替尼单药治疗老年晚期非小细胞肺癌疗效肯定,不良反应相对较小,患者耐受性好。可以作为该特殊人群的一线治疗。Objective： To investigate the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib single-agent first-line treatment for elderly patients with advanced non-small cell lung cancer and its toxicity. Methods： All 36 cases over 65 years of age with advanced non-small cell lung cancer Ⅲ to Ⅳ stage were treated with oral gefitinib 250mg/day, to the disease progress or can not tolerate adverse reactions. Results： All 36 patients could be evaluated the efficacy and toxicity. RR was 41.67% （15/36）, DCR 86.11% （31/36）.The most common side effect was Ⅰ, Ⅱ degree of skin rash in 25 cases （52.78%）, diarrhea in 11 cases （30.56%）,itching of skin in 5 cases （13.89%）, dry skin in 5 cases （13.89%）,2 cases of abnormal liver function accounted for 5.56%.TTP time was 3.5-23.8 months, median TTP 8.2 months. Conclusion： Gefitinib therapy in elderly patients with advanced non-small cell lung cancer treatment, toxicity is relatively small and well tolerated and effective.

关 键 词：吉非替尼 老年患者 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]